Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): Comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride

Diabetes Research and Clinical Practice

Volumn 86, Issue 1, 2009, Pages 31-36

  Ebato, C ^a   Shimizu, T ^a   Arakawa, M ^a   Mita, T ^a   Fujitani, Y ^a   Watada, H ^a   Kawamori, R ^a   Hirose, T ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Algorithm; Biphasic insulin aspart 30; Insulin therapy; Sulfonylurea(s); Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ALGORITHM; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTERVENTION STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 69849086824     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.07.008     Document Type: Article

References (18)

1. International Diabetes Federation. Diabetes atlas. 2nd ed. (2003), International Diabetes Federation, Brussels, Belgium
2. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 44 (1995) 1249-1258
3. Levy J., Atkinson A.B., Bell P.M., McCance D.R., and Hadden D.R. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet. Med. 15 (1998) 290-296
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
5. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28 (1995) 103-117
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329 (1993) 977-986
7. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
8. International Diabetes Federation. Clinical guidelines task force. Global guideline for type 2 diabetes (2005), International Diabetes Federation, Brussels, Belgium
9. Turner R.C., Cull C.A., Frighi V., and Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 (1999) 2005-2012
10. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 31 (2008) 173-175
11. Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab. Res. Rev. 24 (2008) 3-13
12. Masuda H., Sakamoto M., Irie J., Kitaoka A., Shiono K., Inoue G., et al. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients. Diabetes Obes. Metab. (2008)
13. Garber A.J., Wahlen J., Wahl T., Bressler P., Braceras R., Allen E., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes. Metab. 8 (2006) 58-66
14. Hirao K., Arai K., Yamauchi M., Takagi H., and Kobayashi M. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res. Clin. Pract. 79 (2008) 171-176
15. Holman R.R., Thorne K.I., Farmer A.J., Davies M.J., Keenan J.F., Paul S., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med. 357 (2007) 1716-1730
16. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., and Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
17. Tamemoto H., Ikoma A., Saitoh T., Ishikawa S.E., and Kawakami M. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naïve Japanese patients with diabetes. Diabetes Technol. Ther. 9 (2007) 246-253
18. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R.A., Hu P., et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265